BACKGROUND: After age, the second largest risk factor for Alzheimer's disease (AD) is apolipoprotein E (APOE) genotype, where APOE4 is associated with lower apoE protein levels, more severer brain pathology, enhanced inflammation and disease. Small peptides corresponding to the receptor-binding region of apoE mimic the anti-inflammatory activity of the apoE holoprotein. These apoE mimetics greatly improve behavioral outcomes and neuronal survival in head trauma models that display AD pathology and neuronal loss. OBJECTIVE: To determine whether apoE mimetics change behavior, inflammation and pathology in CVND-AD (SwDI-APP/NOS2(-/-)) transgenic mice. METHODS: Starting at 9 months, apoE peptides were subcutaneously administered 3 times per week for 3 months followed by behavioral, histochemical and biochemical testing. RESULTS: Treatment with apoE mimetics significantly improved behavior while decreasing the inflammatory cytokine IL-6, neurofibrillary tangle-like and amyloid plaque-like structures. Biochemical measures matched the visible pathological results. CONCLUSIONS: Treatment with apoE mimetics significantly improved behavior, reduced inflammation and reduced pathology in CVND-AD mice. These improvements are associated with apoE-mimetic-mediated increases in protein phosphatase 2A activity. Testing in additional AD models showed similar benefits, reinforcing this novel mechanism of action of apoE mimetics. These data suggest that the combination of anti-inflammatory and neuroprotective activities of apoE mimetics represents a new generation of potential therapeutics for AD.
BACKGROUND: After age, the second largest risk factor for Alzheimer's disease (AD) is apolipoprotein E (APOE) genotype, where APOE4 is associated with lower apoE protein levels, more severer brain pathology, enhanced inflammation and disease. Small peptides corresponding to the receptor-binding region of apoE mimic the anti-inflammatory activity of the apoE holoprotein. These apoE mimetics greatly improve behavioral outcomes and neuronal survival in head trauma models that display AD pathology and neuronal loss. OBJECTIVE: To determine whether apoE mimetics change behavior, inflammation and pathology in CVND-AD (SwDI-APP/NOS2(-/-)) transgenic mice. METHODS: Starting at 9 months, apoE peptides were subcutaneously administered 3 times per week for 3 months followed by behavioral, histochemical and biochemical testing. RESULTS: Treatment with apoE mimetics significantly improved behavior while decreasing the inflammatory cytokine IL-6, neurofibrillary tangle-like and amyloid plaque-like structures. Biochemical measures matched the visible pathological results. CONCLUSIONS: Treatment with apoE mimetics significantly improved behavior, reduced inflammation and reduced pathology in CVND-ADmice. These improvements are associated with apoE-mimetic-mediated increases in protein phosphatase 2A activity. Testing in additional AD models showed similar benefits, reinforcing this novel mechanism of action of apoE mimetics. These data suggest that the combination of anti-inflammatory and neuroprotective activities of apoE mimetics represents a new generation of potential therapeutics for AD.
Authors: Janet van Eersel; Yazi D Ke; Xin Liu; Fabien Delerue; Jillian J Kril; Jürgen Götz; Lars M Ittner Journal: Proc Natl Acad Sci U S A Date: 2010-07-19 Impact factor: 11.205
Authors: Dale J Christensen; Nobutaka Ohkubo; Jessica Oddo; Michael J Van Kanegan; Jessica Neil; Fengqiao Li; Carol A Colton; Michael P Vitek Journal: J Immunol Date: 2011-02-15 Impact factor: 5.422
Authors: David A Wink; Harry B Hines; Robert Y S Cheng; Christopher H Switzer; Wilmarie Flores-Santana; Michael P Vitek; Lisa A Ridnour; Carol A Colton Journal: J Leukoc Biol Date: 2011-01-13 Impact factor: 4.962
Authors: Daniel T Laskowitz; Pingping Song; Haichen Wang; Brian Mace; Patrick M Sullivan; Michael P Vitek; Hana N Dawson Journal: J Neurotrauma Date: 2010-11-02 Impact factor: 5.269
Authors: R Vidal; M Calero; P Piccardo; M R Farlow; F W Unverzagt; E Méndez; A Jiménez-Huete; R Beavis; G Gallo; E Gomez-Tortosa; J Ghiso; B T Hyman; B Frangione; B Ghetti Journal: Acta Neuropathol Date: 2000-07 Impact factor: 17.088
Authors: John R Lynch; Wen Tang; Haichen Wang; Michael P Vitek; Ellen R Bennett; Patrick M Sullivan; David S Warner; Daniel T Laskowitz Journal: J Biol Chem Date: 2003-09-24 Impact factor: 5.157
Authors: Donna M Wilcock; Matthew R Lewis; William E Van Nostrand; Judianne Davis; Mary Lou Previti; Nastaran Gharkholonarehe; Michael P Vitek; Carol A Colton Journal: J Neurosci Date: 2008-02-13 Impact factor: 6.167
Authors: Aaron J Carman; Rennie Ferguson; Robert Cantu; R Dawn Comstock; Penny A Dacks; Steven T DeKosky; Sam Gandy; James Gilbert; Chad Gilliland; Gerard Gioia; Christopher Giza; Michael Greicius; Brian Hainline; Ronald L Hayes; James Hendrix; Barry Jordan; James Kovach; Rachel F Lane; Rebekah Mannix; Thomas Murray; Tad Seifert; Diana W Shineman; Eric Warren; Elisabeth Wilde; Huntington Willard; Howard M Fillit Journal: Nat Rev Neurol Date: 2015-03-17 Impact factor: 42.937
Authors: Agnieszka Staniszewski; Hong Zhang; Kesava Asam; Rose Pitstick; Michael P Kavanaugh; Ottavio Arancio; Russell E Nicholls Journal: J Neurosci Date: 2020-04-27 Impact factor: 6.167